Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.53 |
| ▸ | TUBB | P07437 | 1/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700056 | 0.82 | RELA (0.84) | CHRM5RELANFE2L2CYP19A1NQO2 | |
| SCHEMBL700055 | 0.82 | RELA (0.84) | CHRM5RELANFE2L2CYP19A1NQO2 | |
| SCHEMBL23158820 | 0.82 | RELA (0.84) | CHRM5RELANFE2L2CYP19A1NQO2 | |
| SCHEMBL2099510 | 0.82 | CHRM5 (0.67) | CHRM5RELANFE2L2CYP19A1NQO2 | |
| SCHEMBL31317665 | 0.82 | RELA (0.84) | CHRM5RELANFE2L2CYP19A1NQO2 | |
| SCHEMBL97058 | 0.80 | CHRM5 (0.64) | CHRM5RELANFE2L2CYP19A1NQO2 | |
| SCHEMBL1483075 | 0.79 | ABL1 (0.53) | CHRM5RELACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL6615780 | 0.78 | CHRM5 (0.62) | CHRM5RELANFE2L2CYP19A1NQO2 | |
| SCHEMBL7684603 | 0.78 | NPC1 (0.65) | CHRM5RELANFE2L2CYP19A1NQO2 | |
| SCHEMBL23188 | 0.78 | NPC1 (0.65) | CHRM5RELANFE2L2CYP19A1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-09-04 | — | — | US | claimed |
| EP-3051946-B1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2017-11-29 | — | — | EP | claimed |
| US-20160237035-A1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | US | claimed |
| EP-3051946-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049351-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AG (DE) | 2015-04-09 | — | — | WO | claimed |
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | claimed |
| EP-2213666-B1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | LI JIAMING (CN) | 2012-02-15 | — | — | EP | claimed |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2010-09-09 | — | — | US | claimed |
| EP-2213666-A1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | Li, Jiaming (CN) | 2010-08-04 | — | — | EP | claimed |
| JP-2006518738-A | — | — | 2006-08-17 | — | — | JP | claimed |
| CN-1747936-A | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA INC (US) | 2006-03-15 | — | — | CN | claimed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2004071447-A9 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2005-10-13 | — | — | WO | claimed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | claimed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| US-6177443-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2001-01-23 | — | — | US | claimed |
| US-6090797-A | ADJUSTMENT OF GLUCOSE METABOLISM; HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2000-07-18 | — | — | US | claimed |
| WO-2000014090-A1 | 4,5,6,7-TETRAHYDRO-THIENO[2,3-C]PYRIDINE DERIVATIVES | NOVO NORDISK A/S (DK) | 2000-03-16 | — | — | WO | claimed |
| EP-0973778-A1 | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-01-26 | — | — | EP | claimed |
| WO-1998040385-A1 | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-09-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | CHRM5 4087/4885RELA 3971/4885NFE2L2 2112/4885 |
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | SQOR, DHPS, QDPR | CHRM5 3909/4885RELA 1484/4885NFE2L2 233/4885 |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | AHR, CYP3A5, CYP3A43 | CHRM5 1018/4885RELA 1505/4885NFE2L2 452/4885 |
| US-20160237035-A1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | SQOR, DHPS, QDPR | CHRM5 3909/4885RELA 1484/4885NFE2L2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.